Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -3.43 is 2418% below its 5-year average of 0.15, around the middle of its 5-year range (-10.07–3.80).
As of the fiscal period ended Tuesday, June 30, 2026. 1.60% below its 12-month average of -3.37.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -3.43.
DEBT TO EQUITY RATIO
-3.43
DEBT TO EQUITY RATIO AVG TTM
-3.37
DEBT TO EQUITY RATIO AVG 3Y
-0.22
DEBT TO EQUITY RATIO AVG 5Y
0.15
DEBT TO EQUITY RATIO AVG 10Y
0.05
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-1.60%
CURRENT VS 3Y AVG
-1451.73%
CURRENT VS 5Y AVG
-2418.30%
CURRENT VS 10Y AVG
-6573.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 470 covered companies
CURRENT VS SECTOR MEDIAN
-2548.28%
vs the sector median at left
electroCore, Inc.
Market Cap
$91.96M
Debt to Equity Ratio
-3.43
TTM Avg
-3.37
3Y Avg
-0.22
5Y Avg
0.15
Market Cap
$91.82M
Debt to Equity Ratio
0.07
TTM Avg
0.11
3Y Avg
0.07
5Y Avg
0.06
Market Cap
$88.63M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$88.84M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$88.52M
Debt to Equity Ratio
0.40
TTM Avg
0.52
3Y Avg
0.53
5Y Avg
0.47
Market Cap
$85.60M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$83.97M
Debt to Equity Ratio
N/A
TTM Avg
0.33
3Y Avg
0.19
5Y Avg
0.13
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $91.96M | -3.43 | -3.37 | -0.22 | 0.15 |
| Biomea Fusion, Inc. (BMEA)vs › | $91.82M | 0.07 | 0.11 | 0.07 | 0.06 |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | 0.02 | 0.02 | 0.03 | 0.02 |
| Equillium, Inc. (EQ)vs › | $89.78M | 0.01 | 0.03 | 0.10 | 0.12 |
| Conexeu Sciences Inc. (CNXU)vs › | $88.84M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $88.52M | 0.40 | 0.52 | 0.53 | 0.47 |
| CareCloud, Inc. (CCLD)vs › | $87.11M | 3.10 | 0.07 | 0.16 | 0.15 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | 0.02 | 0.02 | 0.03 | 0.03 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.97M | N/A | 0.33 | 0.19 | 0.13 |
| Humacyte, Inc. (HUMA)vs › | $84.55M | 2.12 | 20.86 | 8.51 | 5.27 |
Debt/Equity
-3.43
Current Ratio
1.21
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -3.43 |
| 2026-03-31 | -1.67 |
| 2025-12-31 | -5.50 |
| 2025-09-30 | -10.07 |
| 2025-06-30 | 3.80 |
| 2025-03-31 | 0.96 |
| 2024-12-31 | 0.55 |
| 2024-09-30 | 0.43 |
| 2024-06-30 | 0.35 |
| 2024-03-31 | 0.37 |
| 2023-12-31 | 0.08 |
| 2023-09-30 | 0.06 |
| 2023-06-30 | 0.09 |
| 2023-03-31 | 0.06 |
| 2022-12-31 | 0.04 |
| 2022-09-30 | 0.03 |
| 2022-06-30 | 0.03 |
| 2022-03-31 | 0.02 |
| 2021-12-31 | 0.02 |
| 2021-09-30 | 0.03 |
| 2021-06-30 | 0.06 |
| 2021-03-31 | 0.11 |
| 2020-12-31 | 0.12 |
| 2020-09-30 | 0.13 |
| 2020-06-30 | 0.15 |
| 2020-03-31 | 0.11 |
| 2019-12-31 | 0.08 |
| 2019-09-30 | 0.08 |
| 2019-06-30 | 0.05 |
| 2019-03-31 | 0.08 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 680.13 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
